{"id":146199,"date":"2024-02-01T13:42:44","date_gmt":"2024-02-01T12:42:44","guid":{"rendered":"https:\/\/eurecat.org\/?post_type=avada_portfolio&p=146199"},"modified":"2024-09-26T12:48:29","modified_gmt":"2024-09-26T10:48:29","slug":"hypiend","status":"publish","type":"avada_portfolio","link":"https:\/\/eurecat.org\/en\/portfolio-items\/hypiend\/","title":{"rendered":"HYPIEND"},"content":{"rendered":"

\"HYPIEND<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>

<\/h3><\/span>
<\/div><\/div><\/div>

Understanding and preventing the impact of endocrine disruptors on the hypothalamus-pituitary axis in sensitive populations.<\/strong><\/p>\n

The HYPIEND<\/strong> project, coordinated by Eurecat, investigates the effects of multiple endocrine disrupting chemicals (EDC) exposure in the function and epigenetic programming of the hypothalamus-pituitary (HP) axis to delineate interventional strategies for minimizing exposure and consequences on the neuroendocrine system during the perinatal and pre-pubertal stages<\/strong>.<\/p>\n

To do that, a computational toxicology methodological framework<\/strong> will be built leveraging public data and state of the art data analysis techniques to define EDC co-exposure patterns in target population.<\/p>\n

The resulting patterns will be evaluated in a sequential tiered approach<\/strong> consisting in cell-based screenings, Danio rerio models of HP axes, in vitro, in silico and in vivo models of placenta and blood brain barrier diffusion and new models of organoids-based organ-on-chip recapitulating the HP axis.<\/p>\n

EDC effects on epigenetic programming will be evaluated in preclinical models of perinatal and early childhood. Whole genome DNA methylation patterns in the different models will be explored as a source of non-invasive biomarkers of HP axis disruption by EDC.<\/p>\n

The knowledge generated in preclinical models will be applied in two multi-centre-controlled intervention studies <\/strong>intended to minimize exposure to EDC in children in the perinatal and pre-puberty stages.<\/p>\n

HYPIEND outcomes will be novel approach methodologies based in in vitro and in silico models<\/strong>, non-invasive biomarkers of HP disruption by EDC<\/strong> and new intervention strategies to minimize EDC exposure in sensitive population<\/strong>.<\/p>\n

Eurecat leads the HYPIEND project and, through its Units of Nutrition and Health<\/a> and Omic Sciences<\/a>, takes charge of different tasks:<\/p>\n